$SRRK

FLIER JEFFREY S. sold $164K of SRRK

FLIER JEFFREY S. sold 3,053 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.88 ($53.53–$54.88, $0.16M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FLIER JEFFREY S.
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
high confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The disclosed open-market sale by a director, executed under a pre-arranged 10b5-1 plan, is typically not a standalone fundamental driver for the stock.

02

Market read

Traders may note the insider selling signal, but the 10b5-1 structure suggests limited incremental information for valuation.

03

What to watch

The article does not state whether the director’s remaining holdings changed meaningfully versus prior plans, nor does it provide context on total compensation or prior sale cadence.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-06 for a sale executed 2026-07-01.

Background

The article is an SEC Form 4 insider transaction disclosure for Scholar Rock Holding Corp (SRRK).

Company-level read

Ticker impact

$SRRKNeutralHigh confidence
Context

Scholar Rock Holding director Jeffrey S. Flier sold about 3,053 shares in open-market transactions under a 10b5-1 plan, totaling $164,490.

Expected impact

Limited near-term impact; any effect is likely short-lived unless paired with other negative company news.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through from a single director sale under 10b5-1.

None indicated.

None indicated.

Counterpoint

Insider sales can still coincide with private information, but the 10b5-1 designation materially lowers that probability.

Key entities

  • Scholar Rock Holding Corp

    Company whose director insider sale is disclosed via SEC Form 4.

  • FLIER JEFFREY S.

    Director who sold shares in open-market transactions under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRRKMedAI 9/10

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

Scholar Rock Holding (SRRK) received FDA approval for ISEMBYLD, a treatment for spinal muscular atrophy in patients aged 2+. The drug showed a 2.2-point advantage over placebo in motor ability tests. The company is launching the product in the U.S., with support programs for insurance and infusions. Commercial success depends on patient access and treatment persistence, with safety concerns and reimbursement terms being key factors.

$SRRKMed

SRRK Maintained by Evercore ISI Group -- Price Target Raised to

Evercore ISI Group analyst Cory Kasimov maintained an 'Outperform' rating on Scholar Rock Holding Corp (SRRK) and raised the price target from $65.00 to $72.00, a 10.77% increase. SRRK's current price is $47.34 with a market cap of $5.77 billion. The company's GF Score™ is 29/100, indicating room for improvement in financial metrics. Insider activity shows $923,107 in sales over the last three months. The company focuses on biotechnology, developing therapies for rare neuromuscular diseases.

$SRRKHighAI 9/10

Scholar Rock wins FDA approval for spinal muscle atrophy drug

Scholar Rock received FDA approval for Isembyld, a drug targeting muscle loss in spinal muscular atrophy (SMA). The approval follows successful clinical trials showing improved motor skills in patients. The drug is approved for use with existing SMA therapies. Scholar Rock, valued at $6.8B, addressed manufacturing issues before resubmission. Pricing details are pending.